Roivant Sciences (ROIV) EBITDA Margin (2020 - 2026)
Roivant Sciences' (ROIV) quarterly EBITDA Margin came in at 16207.46% in Q4 2025, down 1286375.0% YoY from N/an in Q4 2024, and up 16.85% on a QoQ basis from 19492.87% in Q3 2025.
Roivant Sciences (ROIV) EBITDA Margin (2020 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 6 years of EBITDA Margin data on file, last reported at 16207.46% in Q4 2025.
- Quarterly EBITDA Margin fell 1286375.0% year-over-year to 16207.46% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 7233.54% (down 1411263.0% YoY) and the FY2026 annual result came in at 6235.69%, down 278237.0% from the prior year.
- EBITDA Margin advanced to 16207.46% in Q4 2025, from 19492.87% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 21641.22% in Q4 2023 to a low of 19492.87% in Q3 2025.
- A 5-year average of 4492.46% and a median of 3343.71% in 2024 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2023 — EBITDA Margin surged 2441716 bps — and 2024, when it sank 2498493 bps.
- Tracing ROIV's EBITDA Margin over 5 years: stood at 2355.12% in 2021, then declined by 18 bps to 2775.93% in 2022, then soared by 880 bps to 21641.22% in 2023, then slumped by 115 bps to 3343.71% in 2024, then sank by 385 bps to 16207.46% in 2025.
- The last three EBITDA Margin figures came in at 16207.46% (Q4 2025), 19492.87% (Q3 2025), and 13130.05% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -25,380.93% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -25,380.93% |
| Dec 31, 2025 | -16,207.46% |
| Sep 30, 2025 | -19,492.87% |
| Jun 30, 2025 | -13,130.05% |
| Dec 31, 2024 | -3,343.71% |
| Sep 30, 2024 | -7,636.04% |
| Jun 30, 2024 | -1,279.54% |
| Dec 31, 2023 | 21,641.22% |
| Sep 30, 2023 | -5,863.24% |
| Jun 30, 2023 | -1,278.27% |
| Dec 31, 2022 | -2,775.93% |
| Sep 30, 2022 | -2,240.21% |
| Jun 30, 2022 | -6,536.44% |
| Dec 31, 2021 | -2,355.12% |
| Sep 30, 2021 | -4,893.32% |
| Jun 30, 2021 | -1,995.95% |
| Dec 31, 2020 | -4,505.57% |
| Sep 30, 2020 | -11,832.28% |
| Jun 30, 2020 | -7,262.25% |